EngMab AG

Celgene Corp. 's aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its

Financings Biopharma companies closed out 2016 with $9.6 billion in financing. ( See Exhibit 1. ) Not only was this a 30% increase over Q3's $7.4 billion, it was also the strongest quarter of the year

Biopharma start-ups brought in nearly two-and-a-half times as much funding in the fourth quarter as in the third quarter. Novartis AG was one of five big pharma companies to pen an alliance with a